EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Addressing blinding in classic psychedelic studies with innovative active placebos

Jacob S Aday iD, Otto Simonsson iD, Emmanuelle A D Schindler, Deepak Cyril D'Souza

International Journal of Neuropsychopharmacology · 2025

DOI: 10.1093/ijnp/pyaf023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Neuropsychopharmacology, 2025. Verfasst von Jacob S Aday und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, University of Michigan, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: Hallucinogens, Placebo Effect, Mental Disorders, Clinical Trials as Topic. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Olle Engvist Foundation, NIAMS NIH HHS, VA R&D.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Classic psychedelics have shown promise in the treatment of various neuropsychiatric disorders. However, weak blinding integrity has been argued to limit the interpretability of therapeutic effects observed in psychedelic clinical trials, highlighting the need to explore alternative active placebos. Here, we aimed to describe the drawbacks of current placebo conditions used in classic psychedelic studies, propose criteria for suitable active placebos, and review interventions that may putatively fit these criteria. Considerations for the characteristics of ideal active placebos in classic psychedelic studies include (1) acute psychoactive effects, (2) acute physiological effects, (3) onset and duration of acute effects, (4) safety, and (5) lack of therapeutic effects in the target disease. We identified several pharmacological agents that may have potential as active placebos in trials involving moderate-to-high doses of certain short-acting and long-acting classic psychedelics, as well as low-dose administration and microdosing regimes. To accurately assess the safety and efficacy of classic psychedelics as therapeutics, future research should apply a thoughtful process for selecting active placebos and consider ancillary strategies to improve blinding in trials involving these substances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensPlacebo EffectMental DisordersClinical Trials as TopicHumansPlacebosResearch DesignDouble-Blind Method

Stichwörter der Autor:innen

active placebosblindingcontrol conditionspsychedelicsreview

Substanzen

HallucinogensPlacebos

Autor:innen und Institutionen

  • Department of Anesthesiology, University of Michigan, Ann Arbor, MI, United States.
  • Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Sweden.
  • Department of Neurology, Yale School of Medicine, New Haven, CT, United States.
  • Neurology Service, VA Connecticut Healthcare System, West Haven, CT, United States.
  • Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States.
  • Neuropsychiatry Firm, VA Connecticut Healthcare System, West Haven, CT, United States.

ORCID-Profile: Jacob S Aday, Otto Simonsson

Förderung

  • Olle Engvist Foundation
  • NIAMS NIH HHS
  • VA R&D
  • Vikram Sodhi Endowed Chair of Psychiatry
  • Ceruvia Lifesciences
  • Wallace Research Foundation
  • Heffter Research Institute
  • Clusterbusters, Inc

Zitieren

APA

Aday, J. S., Simonsson, O., Schindler, E. A. D., & D'Souza, D. C. (2025). Addressing blinding in classic psychedelic studies with innovative active placebos. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaf023

Vancouver

Aday JS, Simonsson O, Schindler EAD, D'Souza DC. Addressing blinding in classic psychedelic studies with innovative active placebos. International Journal of Neuropsychopharmacology. 2025. doi:10.1093/ijnp/pyaf023

BibTeX
@article{Aday2025,
  author = {Aday, Jacob S and Simonsson, Otto and Schindler, Emmanuelle A D and D'Souza, Deepak Cyril},
  title = {Addressing blinding in classic psychedelic studies with innovative active placebos},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2025},
  doi = {10.1093/ijnp/pyaf023}
}
Kostenlos starten →